Application of the Modified Rankin Scale in Outcome Assessment for Stroke Clinical Trials and Research on Statistical Methods

doi:10.3969/j.issn.1673-5765.2025.08.012

Abstract

Abstract: The mRS is a commonly used endpoint assessment tool in stroke clinical trials. However, many current clinical trials still lack standardized definitions of health conditions corresponding to different mRS cut-off points, and the statistical analysis methods applicable to mRS also vary in different clinical trials. This article aims to provide an overview of the application of mRS in stroke clinical trials and discusses the recommended terminology and statistical analysis methods of mRS.

Key words: Modified Rankin scale; Stroke; Clinical trial

摘要： mRS是卒中临床试验中常用的终点评估工具。然而，目前许多临床试验对不同mRS切点对应健康状况的定义仍欠规范，mRS的统计分析方法在不同临床试验中也存在差异。本文旨在对mRS在卒中临床试验中的应用进行概述，并对mRS的推荐术语及统计分析方法进行重点讨论。

关键词: 改良Rankin量表; 卒中; 临床试验

CLC Number:

ZHU Jinqiao, XIA Xue, XU Qin, FENG Tao, WANG Anxin. Application of the Modified Rankin Scale in Outcome Assessment for Stroke Clinical Trials and Research on Statistical Methods[J]. Chinese Journal of Stroke, 2025, 20(8): 1029-1034.

朱金巧, 夏雪, 胥芹, 冯涛, 王安心. 改良Rankin量表用于卒中临床试验结局评价及其统计方法研究[J]. 中国卒中杂志, 2025, 20(8): 1029-1034.

References

[1] QUINN T J，DAWSON J，WALTERS M R，et al. Functional outcome measures in contemporary stroke trials[J]. Int J Stroke，2009，4（3）：200-205.
[2] LEES K R，BATH P M W，SCHELLINGER P D，et al. Contemporary outcome measures in acute stroke research：choice of primary outcome measure[J]. Stroke，2012，43（4）：1163-1170.
[3] DUNCAN P W，JORGENSEN H S，WADE D T. Outcome measures in acute stroke trials：a systematic review and some recommendations to improve practice[J]. Stroke，2000，31（6）：1429-1438.
[4] RANKIN J. Cerebral vascular accidents in patients over the age of 60. Ⅱ. Prognosis[J]. Scott Med J，1957，2（5）：200-215.
[5] FARRELL B，GODWIN J，RICHARDS S，et al. The United Kingdom transient ischaemic attack（UK-TIA）aspirin trial：final results[J]. J Neurol Neurosurg Psychiatry，1991，54（12）：1044-1054.
[6] VAN SWIETEN J C，KOUDSTAAL P J，VISSER M C，et al. Interobserver agreement for the assessment of handicap in stroke patients[J]. Stroke，1988，19（5）：604-607.
[7] JOVIN T G，CHAMORRO A，COBO E，et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med，2015，372（24）：2296-2306.
[8] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[9] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[10] 国家食品药品监督管理总局. 总局关于发布急性缺血性脑卒中治疗药物临床试验技术指导原则的通告（2018年第28号）[EB/OL].（2018-02-09）[2025-02-20]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypggtg/ypqtggtg/20180209175801578 html.
[11] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性脑卒中临床研究规范共识2018[J]. 中华神经科杂志，2018，51（4）：247-255.
Chinese Society of Neurology，Chinese Stroke Society. Chinese expert consensus on clinical research standards for acute stroke（2018）[J]. Chin J Neurol，2018，51（4）：247-255.
[12] 范玉华，姬晓昙，蓝琳芳. 国内脑卒中临床试验疗效判断方法中改良Rankin评分的应用现状[J]. 中国神经精神疾病杂志，2015，41（7）：412-415.
FAN Y H，JI X T，LAN L F. The application of mRS in the methods of outcome assessment in Chinese stroke trials[J]. Chin J Nerv Ment Dis，2015，41（7）：412-415.
[13] BRUNO A，AKINWUNTAN A E，LIN C，et al. Simplified modified Rankin scale questionnaire：reproducibility over the telephone and validation with quality of life[J]. Stroke，2011，42（8）：2276-2279.
[14] DUTTA D，FOY C，RAMADURAI G，et al. Initial testing of an electronic application of the simplified modified Rankin scale questionnaire（e-smRSq）[J/OL]. J Stroke Cerebrovasc Dis，2020，29（9）：105024[2025-02-20]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105024.
[15] BRODERICK J P，ADEOYE O，ELM J. Evolution of the modified Rankin scale and its use in future stroke trials[J]. Stroke，2017，48（7）：2007-2012.
[16] SAVER J L，CHAISINANUNKUL N，CAMPBELL B C V，et al. Standardized nomenclature for modified Rankin scale global disability outcomes：consensus recommendations from Stroke Therapy Academic Industry Roundtable Ⅺ[J]. Stroke，2021，52（9）：3054-3062.
[17] World Health Organization. Towards a common language for functioning，disability and health[EB/OL].
（2002-01-01）[2025-02-20]. https://www.who.int/publications/m/item/icf-beginner-s-guide-towards-a-common-language-for-functioning-disability-and-health.
[18] HUYBRECHTS K F，CARO J J，XENAKIS J J，et al. The prognostic value of the modified Rankin scale score for long-term survival after first-ever stroke. Results from the Athens stroke registry[J]. Cerebrovasc Dis，2008，26（4）：381-387.
[19] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[20] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[21] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[22] Stroke Therapy Academic Industry Roundtable（STAIR）. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke，1999，30（12）：2752-2758.
[23] HACKE W，KASTE M，FIESCHI C，et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke（ECASS Ⅱ）[J]. Lancet，1998，352（9136）：1245-1251.
[24] BATH P M W，LEES K R，SCHELLINGER P D，et al. Statistical analysis of the primary outcome in acute stroke trials[J]. Stroke，2012，43（4）：1171-1178.
[25] SAVER J L，GORNBEIN J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials[J]. Neurology，2009，72（15）：1310-1315.
[26] ADAMS H J，LECLERC J R，BLUHMKI E，et al. Measuring outcomes as a function of baseline severity of ischemic stroke[J]. Cerebrovasc Dis，2004，18（2）：124-129.
[27] MURRAY G D，BARER D，CHOI S，et al. Design and analysis of phase Ⅲ trials with ordered outcome scales：the concept of the sliding dichotomy[J]. J Neurotrauma，2005，22（5）：511-517.
[28] YOUNG F B，LEES K R，WEIR C J. Improving trial power through use of prognosis-adjusted end points[J]. Stroke，2005，36（3）：597-601.
[29] FENG C Y，WANG H Y，WANG B K，et al. Relationships among three popular measures of differential risks：relative risk，risk difference，and odds ratio[J]. Shanghai Arch Psychiatry，2016，28（1）：56-60.
[30] ROBBINS A S，CHAO S Y，FONSECA V P. What’s the relative risk？A method to directly estimate risk ratios in cohort studies of common outcomes[J]. Ann Epidemiol，2002，12（7）：452-454.
[31] WACHOLDER S. The case-control study as data missing by design：estimating risk differences[J]. Epidemiology，1996，7（2）：144-150.
[32] BERKHEMER O A，FRANSEN P S S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.
[33] GOYAL M，DEMCHUK A M，MENON B K，et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med，2015，372（11）：1019-1030.
[34] HACKE W，KASTE M，FIESCHI C，et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study（ECASS）[J]. JAMA，1995，274（13）：1017-1025.
[35] HONG K S，SAVER J L. Quantifying the value of stroke disability outcomes：WHO global burden of disease project disability weights for each level of the modified Rankin scale[J]. Stroke，2009，40（12）：3828-3833.
[36] DIJKLAND S A，VOORMOLEN D C，VENEMA E，et al. Utility-weighted modified Rankin scale as primary outcome in stroke trials：a simulation study[J]. Stroke，2018，49（4）：965-971.
[37] CHAISINANUNKUL N，ADEOYE O，LEWIS R J，et al. Adopting a patient-centered approach to primary outcome analysis of acute stroke trials using a utility-weighted modified Rankin scale[J]. Stroke，2015，46（8）：2238-2243.
[38] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.